Study phase | Run-in period | Intervention period | ||||
---|---|---|---|---|---|---|
Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
Time | -14 days | 0 day | 2 weeks | 4 weeks | 6 weeks | 8 weeks |
Baseline data collection | ||||||
Informed consent | × | |||||
Inclusion/exclusion criteria | × | |||||
Demographic data | × | |||||
Get the central random number | × | |||||
Concomitant disease and treatment | × | |||||
Previous history、medical history and allergies | × | |||||
Safety evaluation | ||||||
Vital signs | × | × | × | × | × | × |
Complete blood count, urine and stool tests | × | × | ||||
Liver and renal function tests | × | × | ||||
Coagulation function test | × | × | ||||
Cardiovascular events | × | × | × | × | × | × |
Adverse event evaluation | × | × | × | × | × | × |
Efficiency evaluation | ||||||
Exercise treadmill testing’ | × | × | × | |||
TCM syndrome score | × | × | × | × | × | × |
GAD-7 score | × | × | × | × | × | × |
CCS angina classification | × | × | × | × | × | × |
SF-36 score | × | × | × | × | × | × |
Nitroglycerin consumption | × | × | × | × | × | × |
Other work | ||||||
Concomitant medications | × | × | × | × | × | × |
Dispense drug | × | × | × | × | × | |
Recovery and record of study drug | × | × | × | × | × | |
Evaluate the adherence | × | × | × | × | × | |
Study completion status | × | × | × | × | ||
CRF examination | × |